AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Diseases
· Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin · Lead indication is non-CF bronchiectasis; ATL-105 targe
AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development
Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026 Munich, Germany – 15.0
AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board
Leading Expert in Respiratory Medicine Supporting AATec in Product Development in Non-CF Bronchiectasis Munich, Germany – 18.09.2024 – AATec Medical GmbH (AATec), a biotech com